Opis działalności
Nektar Therapeutics is a research-based, development stage biopharmaceutical company whose mission is to discover and develop innovative medicines to address the unmet medical needs of patients. The R&D pipeline of new investigational medicines includes treatments for cancer, auto-immune disease and chronic pain. Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India.
Zarząd & Rada nadzorcza
| CEO |
| Howard W. Robin |
| Zarząd |
| Gil M. Labrucherie, Brian L. Kotzin, M.D., Dr. Dimitry S.A. Nuyten, Dr. Jonathan Zalevsky, Dr. Kevin Brodbeck, Dr. Urte Gayko, Jennifer Ruddock, Jilian B. Thomsen, John Northcott, Mark A. Wilson, Mary Tagliaferri, M.D., Robert Bacci |
| Rada nadzorcza |
| Robert B. Chess, Diana M. Brainard, Dr. Myriam J. Curet, Howard W. Robin, Jeff Ajer, Karin Eastham, R. Scott Greer, Roy A. Whitfield |
Dane firmy
| Nazwa: |
Nektar Therapeutics Inc. |
| Adres: |
455 Mission Bay Boulevard South,San Francisco, CA 94158, USA |
| Telefon: |
+1-415-482-5300 |
| Fax: |
+1-415-339-5300 |
| E-mail: |
-
|
| Internet: |
https://www.nektar.com/ |
| Przemysł: |
Służba zdrowia |
| Sektor: |
Przemysł Farmaceutyczny |
| Podsektor: |
Przemysł Farmaceutyczny |
| Koniec roku finansowego: |
31.12 |
| Free float: |
- |
| Data IPO: |
- |
Relacje inwestorskie
| Nazwa: |
Vivian Wu |
| Telefon: |
+1-628-895-0661 |
| Fax: |
- |
| E-mail: |
-
|
